Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 17/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845839 | 0.88 | SLC16A1 (0.50) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3827762 | 0.87 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL10292857 | 0.86 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3826819 | 0.83 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4ABCB11LMNA | |
| SCHEMBL4804153 | 0.80 | SLC16A1 (0.56) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3830716 | 0.78 | SLC16A1 (0.53) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3828120 | 0.78 | SLC16A1 (0.66) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL5096845 | 0.78 | SLC16A1 (0.67) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL7944970 | 0.78 | SLC16A1 (0.68) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL3833822 | 0.78 | SLC16A1 (0.50) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | SLC16A1 4571/4885CYP2C9 4869/4885CYP3A4 4851/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC16A1 3634/4885CYP2C9 4746/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.